Pre-Open Stock Movers 02/05: (AMRS) (ALLT) (EL) Higher; (OPK) (HLIT) (GLUU) Lower (more...)

February 5, 2019 9:23 AM

Today's Pre-Open Movers

Amyris, Inc. (Nasdaq: AMRS) 39.2% HIGHER; announced that it has signed a binding term sheet for a planned cannabinoid development, licensing and commercialization partnership valued at up to $255 million (not including significant royalties once the products are commercialized) with a confidential partner. The $255 million in payments include an upfront payment and the remainder are linked to milestones that are expected over the next 12-36 months following the signing of a definitive final agreement. Amyris has a successful track record of leveraging its unique technology platform to scale No Compromise sustainable products and successfully bring them to commercialization. In addition to lab-based milestone payments, this agreement also provides for significant milestone payments for commercially scaling each product.

OPKO Health, Inc. (NASDAQ: OPK) 19% LOWER; announced that, subject to market and other conditions, it intends to offer $200 million aggregate principal amount of Convertible Senior Notes due 2025 in an underwritten public offering. The Notes will be general senior unsecured obligations of the Company, will pay interest semiannually in arrears and will be convertible into, at the Companys election, cash, shares of the Companys common stock, or a combination of cash and common stock, as further described in the prospectus supplement. The Company intends to grant the underwriter an option to purchase up to an additional $30 million aggregate principal amount of the Notes to cover over-allotments, if any.

Harmonic (NASDAQ: HLIT) 13.9% LOWER; reported Q4 EPS of $0.11, $0.06 better than the analyst estimate of $0.05. Revenue for the quarter came in at $113.6 million versus the consensus estimate of $112.95 million

BioLineRx (NASDAQ: BLRX) 11.5% LOWER; commenced an underwritten public offering of American Depositary Shares (ADSs), each representing one of its ordinary shares with each ADS to be sold together in a fixed combination with a warrant to purchase ADSs. All of the securities in the offering are to be sold by BioLineRx. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Allot Communications (NASDAQ: ALLT) 10.3% HIGHER; reported Q4 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $26.9 million versus the consensus estimate of $25.18 million.

Codexis, Inc. (NASDAQ: CDXS) 10% HIGHER; announces the signing of a new agreement with Merck (NYSE: MRK), through a subsidiary. Under the terms of the agreement, Codexis will install certain CodeEvolverĀ® protein engineering technology upgrades into Merckā€™s platform license installation and will maintain those upgrades for a multi-year term. Financial terms of the agreement are undisclosed.

Glu Mobile (NASDAQ: GLUU) 9.8% LOWER; reported Q4 EPS of ($0.01), $0.08 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $95.6 million versus the consensus estimate of $95.98 million.

Estee Lauder (NYSE: EL) 9.3% HIGHER; reported Q2 EPS of $1.86, $0.32 better than the analyst estimate of $1.54. Revenue for the quarter came in at $4 million versus the consensus estimate of $3.92 million. Estee Lauder sees Q1 EPS of $1.26-$1.28, versus the consensus of $1.24.

Rudolph Technologies (NYSE: RTEC) 8.5% LOWER; reported Q4 EPS of $0.29, $0.02 better than the analyst estimate of $0.27. Revenue for the quarter came in at $62.78 million versus the consensus estimate of $62.54 million. Rudolph Technologies sees Q1 2019 EPS of $0.19-$0.25, versus the consensus of $0.32. Rudolph Technologies sees Q1 2019 revenue of $56-63 million, versus the consensus of $66.14 million.

Control4 (NASDAQ: CTRL) 7.3% LOWER; reported Q4 EPS of $0.44, $0.01 better than the analyst estimate of $0.43. Revenue for the quarter came in at $72.5 million versus the consensus estimate of $73.16 million. Control4 sees Q1 2019 EPS of $0.08-$0.11, versus the consensus of $0.22. Control4 sees Q1 2019 revenue of $61-63 million, versus the consensus of $64.43 million. Control4 sees FY2019 EPS of $1.18-$1.25, versus the consensus of $1.54. Control4 sees FY2019 revenue of $295-301 million, versus the consensus of $300.85 million.

Church & Dwight (NYSE: CHD) 7.2% LOWER; reported Q4 EPS of $0.57, $0.01 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion. Mr. Farrell stated, We expect 2019 to be another strong year with EPS of $2.43 to $2.47, an increase of 7-9%, driven by operating income growth. This reflects continued strong business performance in-line with our Evergreen model.

Ralph Lauren (NYSE: RL) 6.6% HIGHER; reported Q3 EPS of $2.32, $0.18 better than the analyst estimate of $2.14. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.66 billion.

Box, Inc. (NYSE: BOX) 6.3% HIGHER; Goldman Sachs initiates coverage with a Buy rating and a price target of $31.00.

Luminex Corp. (NASDAQ: LMNX) 5.6% LOWER; reported Q4 EPS of $0.04, $0.05 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $81.1 million versus the consensus estimate of $79.43 million. Luminex Corp. sees Q1 2019 revenue of $82-84 million, versus the consensus of $85.3 million. Luminex Corp. sees FY2019 revenue of $337-343 million, versus the consensus of $340.53 million

Pitney-Bowes (NYSE: PBI) 5.9% LOWER; reported Q4 EPS of $0.38, in-line with the analyst estimate of $0.38. Revenue for the quarter came in at $947.1 million versus the consensus estimate of $933.17 million. Pitney-Bowes sees FY2019 EPS of $1.05-$1.20, versus the consensus of $1.24. Cuts dividend.

Legg Mason (NYSE: LM) 5.2% LOWER; reported Q3 EPS of $0.73, ex-items, $0.05 better than the analyst estimate of $0.68. Revenue for the quarter came in at $704.3 million versus the consensus estimate of $724.61 million.

Seagate Technology (NASDAQ: STX) 4.9% LOWER; reported Q2 EPS of $1.41, $0.13 better than the analyst estimate of $1.28. Revenue for the quarter came in at $2.7 billion versus the consensus estimate of $2.72 billion.

Regenxbio Inc. (NASDAQ: RGNX) 4.4% HIGHER; Raymond James upgraded from Outperform to Strong Buy with a price target of $94.00.

Gilead Sciences (NASDAQ: GILD) 3.8% LOWER; reported Q4 EPS of $1.44, $0.27 worse than the analyst estimate of $1.71. Revenue for the quarter came in at $5.8 billion versus the consensus estimate of $5.49 billion. Gilead Sciences sees FY2019 revenue of $21.3-21.8 billion, versus the consensus of $21.74 billion. Product Gross Margin 85% - 87%

AMD (NASDAQ: AMD) 3.2% LOWER; investor Mubadala Investment solid 34.9 million shares of AMD and plans to convert 75 million warrants.

Invesco Mortgage Capital Inc. (NYSE: IVR) 3.1% LOWER; announced today that it plans to make a public offering of 14 million shares of its common stock.

Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) 2.6% LOWER; reported Q4 EPS of $12.77, $1.91 better than the analyst estimate of $10.86. Revenue ex-TAC for the quarter came in at $31.84 billion versus the consensus estimate of $31.33 billion. Total fourth quarter revenue grew 22% to $39.276 billion, versus the consensus of $38.98 billion.

Categories

Special Reports

Next Articles